Jonathan Finn, CFA, is a founding member of New Ventures Funds and has worked as an investment professional for over 25 years. He is on the board of managers of the Managing Member of New Ventures I, LLC, New Ventures Select, LLC, New Ventures III, LLC and NVaS Solutions, LLC, and serves as the Chief Investment Officer of the investment manager for the New Ventures Funds.  Mr. Finn graduated from the University of Virginia with a BA in economics and holds the Chartered Financial Analyst designation.

Mr. Finn routinely serves on the board of investee companies and currently represents the Funds as a director of eReceivables, LLC, a healthcare billing business, Verigraft AB, a regenerative medicine venture and Rose Pharma LLC, a development stage specialty pain company. In addition, he is a director of Atossa Therapeutics (NASDAQ: ATOS) a clinical stage biotechnology company focused on oncology and Solör Bioenergy Holdings AB, a Scandinavian bioenergy business. Mr. Finn also currently serves on the investor advisory committee of venture capital funds sponsored by WI Harper and Sinovation Ventures.